A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases

NCT03800472 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: GLPG3312 IR
DRUG: Placebo
DRUG: GLPG3312 MR
DRUG: GLPG3312 FE MR
DRUG: GLPG3312 MR
DRUG: GLPG3312 MR
DRUG: Placebo

Sponsor

Lakefront Biotherapeutics NV